- Home
- BRNS vs SLGL Comparison
BRNS vs SLGL Comparison
Compare BRNS & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- SLGL
- Stock Information
- Founded
- BRNS 2016
- SLGL 1997
- Country
- BRNS United Kingdom
- SLGL Israel
- Employees
- BRNS N/A
- SLGL N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- SLGL Health Care
- Exchange
- BRNS Nasdaq
- SLGL Nasdaq
- Market Cap
- BRNS 58.0M
- SLGL 69.1M
- IPO Year
- BRNS 2021
- SLGL 2018
- Fundamental
- Price
- BRNS $1.61
- SLGL $40.01
- Analyst Decision
- BRNS Strong Buy
- SLGL
- Analyst Count
- BRNS 1
- SLGL 0
- Target Price
- BRNS $3.00
- SLGL N/A
- AVG Volume (30 Days)
- BRNS 248.2K
- SLGL 21.2K
- Earning Date
- BRNS 11-05-2025
- SLGL 11-14-2025
- Dividend Yield
- BRNS N/A
- SLGL N/A
- EPS Growth
- BRNS N/A
- SLGL N/A
- EPS
- BRNS N/A
- SLGL N/A
- Revenue
- BRNS $14,969,000.00
- SLGL $23,931,000.00
- Revenue This Year
- BRNS N/A
- SLGL N/A
- Revenue Next Year
- BRNS N/A
- SLGL $31.17
- P/E Ratio
- BRNS N/A
- SLGL N/A
- Revenue Growth
- BRNS 1766.46
- SLGL 264.86
- 52 Week Low
- BRNS $0.64
- SLGL $4.01
- 52 Week High
- BRNS $2.92
- SLGL $52.26
- Technical
- Relative Strength Index (RSI)
- BRNS 65.26
- SLGL 74.00
- Support Level
- BRNS $1.36
- SLGL $27.00
- Resistance Level
- BRNS $1.67
- SLGL $52.26
- Average True Range (ATR)
- BRNS 0.17
- SLGL 4.40
- MACD
- BRNS 0.05
- SLGL 0.95
- Stochastic Oscillator
- BRNS 72.15
- SLGL 57.87
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.